Brain-computer interface developer building minimally-invasive endovascular implants
Synchron's Stentrode is a stent-mounted electrode array implanted via the jugular vein, avoiding open-brain surgery. First BCI company to receive FDA Investigational Device Exemption (IDE) for human trials in the US. Has implanted devices in patients with ALS to enable computer control via thought.
Biotech📍 Brooklyn, NYFounded 2016
Current Valuation
$1.0B
as of 2024-Q4
UNICORN
QL Price
$1.0B
0% vs last round
QuantLogix's current estimate for Synchron, published 2026-10-08 — in line with the last disclosed round of $1.0B (2024-Q4).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.0B
2024-Q4
weight 0.29
Secondary market print
$1.0B
2026-06-27
weight 0.54
How this price has held up
No round has priced for Synchron since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-08 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Synchron, 2026-10-08 (53d6aebb12ccd2c4).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Synchron going public?
No. Synchron has no imminent IPO plans on record. It is still private.
What is Synchron's valuation in 2026?
Synchron is valued at $1.0B as of 2024-Q4, set by its Series C ($75M, Dec 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Synchron filed an S-1?
No public S-1 is on file for Synchron.
Who are Synchron's investors?
Synchron's investors include ARCH Venture Partners, Khosla Ventures, Bezos Expeditions, Bill Gates, Reliance Industries, NVIDIA.
How much has Synchron raised?
Synchron has raised $145M in total, most recently a Series C of $75M in Dec 2024.
Is Synchron publicly traded — can you buy Synchron stock?
No. Synchron is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Synchron on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Tom Oxley
Founded
2016
HQ
Brooklyn, NY
Employees
~70
Total Raised
$145M
Last Round
Series C — $75M (Dec 2024) · Lead: ARCH Venture Partners
IPO Status
no imminent plans
Fundraising Status
Series C · $75M · 1y 10mo ago
no imminent plansTotal raised $145M
Secondary Market
Implied price / share
$34.68
Open interest
3
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$75M
Dec 2024
ARCH Venture Partners
—
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
3
3 active · 3 recruiting
Focus areas
Motor Neuron Disease
Neurologic Disorder · ALS
Latest trial start
2026-05-22
Name-verified against lead sponsor "Synchron, Inc." on ClinicalTrials.gov as of 2026-10-04. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▼ Hiring downtrend
-44% vs 2026-08
Open roles
5
via careers page
Product-build share
60%
engineering, research, product, design
Trajectory
strengthening
product-led hiring — 60% of open roles build product; the rest are go-to-market and G&A.
Recent senior hire: 1 senior hire (CEO); open roles trending down.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Key Executive Moves
INPat DoranCEO · 2026-08-19
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Synchron MedicalSenior Quality Engineer-Operations-CA (opens in new tab)San Diego, CA→Senior Quality Engineer-New Product Dev- CA (opens in new tab)San Diego, CA→Skip to contentSenior Director, Regulatory Affairs-CA (opens in new tab)San Diego, CA→
Counted from Synchron's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Neuralink · Paradromics · Onward Medical · Blackrock Neurotech
BiotechBCIMedical DeviceBezos Backed
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q4. Refreshed quarterly.